MedTrace Logo

Laser Dosage in MicroPulse TransScleral CycloPhotocoagulation

NCT04709679 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-07-01

No results posted yet for this study

Summary

This is a prospective study to evaluate the clinical outcome of varying doses of Micropulse TransScleral CycloPhotocoagulation (MP-TSCPC) laser in patients with glaucoma. The study will assess documented complication rates, changes in visual acuity after the procedure, changes in intraocular pressures and medication drop usage, and need for subsequent treatments (including further laser or surgery).

Conditions

Interventions

PROCEDURE

MicroPulse TransScleral CycloPhotoCoagulation

A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients

Sponsors & Collaborators

  • IRIDEX Corporation

    collaborator UNKNOWN

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • Sandra F Sieminski, MD · Ross Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-10-11
Completion
2021-10-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04709679 on ClinicalTrials.gov